Granisetron Extended Release Injection (GERSC) for the Prevention of Chemotherapy-induced Nausea and Vomiting

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

August 15, 2020

Primary Completion Date

August 15, 2020

Study Completion Date

December 1, 2022

Conditions
Chemotherapy-induced Nausea and Vomiting
Interventions
DRUG

GRANISETRON EXTENDED RELEASE INJECTION (GERSC)

GERSC is a new, subcutaneously (SC) administered polymeric formulation of granisetron that was developed to provide slow, controlled, and sustained release of granisetron to prevent both acute and delayed CINV associated with MEC and HEC. Due to the prolonged efficacy, GERSC may potentially improve CINV in the acute and delayed periods and the single dose regimen may improve patient adherence to antiemetic therapy

Trial Locations (1)

35294

The University of Alabama at Birmingham, Birmingham

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Heron Therapeutics

INDUSTRY

lead

University of Alabama at Birmingham

OTHER